Health Care • Biotechnology: Pharmaceutical Preparations
$45.23 ▲ +0.98
(+2.22%)
MKT CAP: $2.11B • VOL: 200.7K
52W L $18 52W H $51
SEPN // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $46.0M | $1.1M | $151.0K |
| YoY Revenue Growth % | +4174.5% | +611.9% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$68.3M | -$80.8M | $2.1M |
| Operating Margin % | -80.0% | -80.0% | 85.0% |
| Net Income (GAAP) | -$48.9M | -$71.8M | $4.2M |
| EBITDA (Normalized) | -$67.9M | -$79.1M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $110.2M | -$67.5M | -$38.7M |
| Capital Expenditures (CapEx) | $518.0K | $2.1M | — |
| Free Cash Flow (FCF) | $109.7M | -$69.6M | -$38.7M |
| FCF Margin % | 80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -20.7% | -35.1% | — |
| Cash & Short-Term Equivalents | $120.7M | $238.2M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $381.9M | $420.0M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR SEPN.